Critically ill patients with COVID-19 who are given a drug that reduces inflammation by modifying the immune system require less time receiving intensive care treatment, an international study has found.
Two Wellington-based researchers have been awarded the HRC's prestigious Liley Medal for a study that found patients with mild asthma are much less likely to have a severe asthma attack if they use an inhaler containing a combination of both preventive and reliever medication as needed.
The latest funding grants awarded by the Health Research Council of New Zealand (HRC) provide vital early support for research and researchers wanting to improve patient care and healthcare systems in New Zealand.
The Health Research Council has awarded more than $13.38 million in its annual Career Development Awards. This includes funding for a Māori health research fellowship to investigate the multiple dimensions of cannabis and methamphetamine use.
Research into critically ill patients with COVID-19, published today, shows fewer patients died and less intensive care (ICU) support was required when patients received corticosteroids compared with usual treatment.